SynGen appoints new President of Cell Processing Business Unit

David Hodl is a former Becton Dickinson Business Development Manager

SynGen, a US company that focuses on the development and commercialisation of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, has appointed David Hodl, formerly Business Development Manager at Becton Dickinson, to lead commercialisation efforts for its newly formed Cell Processing Business Unit.

Hodl brings 19 years of experience in product commercialisation and business development in the life science and medical products industry to the position. During his tenure with BD's Corporate Innovation Center, he led the commercialisation of several cell-based technologies, including BD FACS CAP, an antibody-based cell surface marker profiling platform and BD's Discovery Platform, a custom cell culture environment development service.

He also played a leading role in executing the development partnership between BD and Fate Therapeutics to access proprietary technology for developing products for expansion and differentiation of induced pluripotent stem cells.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Manufacturing

Servier opens new €86m biologics production facility in Loiret, France

The company's Bio-S facility will be responsible for the production of biological medicines stemming from its R&D pipeline for preclinical and clinical studies
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Digital

Why CGT manufacturers should automate the production process

Cell and gene therapies can be highly complex and time-consuming to produce at scale; full robotic automation could help biologics manufacturers to make processes more space, personnel and cost efficient
Subscribe now